Pazopanib - GlaxoSmithKline/Novartis

Alternative Names: 786034; Armala; GW-786034; GW-786034B; Pazopanib hydrochloride; SB-786034; Votrient

Latest Information Update: 12 Apr 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GlaxoSmithKline
Developer Charite - Universitatsmedizin Berlin; Duke University Medical Center; GlaxoSmithKline; GSK; Masonic Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; Samsung Medical Center; SCRI Development Innovations; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of California at Irvine; University of Heidelberg; University of Minnesota; University of Oxford; University of Washington; Washington University School of Medicine
Class Amines; Antineoplastics; Indazoles; Pyrimidines; Small molecules; Sulfonamides
Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Renal cell carcinoma; Sarcoma
Phase II Acute myeloid leukaemia; Bladder cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Haemangiosarcoma; Liposarcoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Urogenital cancer
No development reported Colorectal cancer; Head and neck cancer; Liver cancer
Discontinued Age-related macular degeneration; Hereditary haemorrhagic telangiectasia; Inflammatory breast cancer

Most Recent Events

26 Feb 2024 Efficacy, pharmacokinetics and adverse events data from a phase I/II PAZOGLIO trial in Glioblastoma presented at the ESMO Targeted Anticancer Therapies Congress 2024 (TAT-2024)
02 Jun 2023 Adverse events data from a phase I/II PAZOGLIO trial in Glioblastoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology 2023 (ASCO-2023)
07 Jul 2022 3683668 - Clinical data of NIO sponsored trial, hence not covered

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight